Skip to content
MarketScale
‹ Back to IndustriesSciences

The Impact of the Russian ASAT Tests

In this bonus episode of Space to Grow, hosts Charity Weeden and Chris Blackerby  sit down to discuss kinetic ASAT tests in space and possible silver-linings that came from the most recent test. The November 2021 Russian ASAT (Anti-Satellite) test shed unprecedented light onto the space community and is estimated to have produced almost 1700 pieces of…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · AsatBanDebrisRussia
Share

Key takeaways

01

In this bonus episode of Space to Grow, hosts Charity Weeden and Chris Blackerby  sit down to discuss kinetic ASAT tests in space and possible silver-linings that came from the most recent test.

02

The November 2021 Russian ASAT (Anti-Satellite) test shed unprecedented light onto the space community and is estimated to have produced almost 1700 pieces of…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

In this bonus episode of Space to Grow, hosts Charity Weeden and Chris Blackerby sit down to discuss kinetic ASAT tests in space and possible silver-linings that came from the most recent test.

The November 2021 Russian ASAT (Anti-Satellite) test shed unprecedented light onto the space community and is estimated to have produced almost 1700 pieces of debris in the 600km range, close to Earth, which was spread throughout other orbital regimes.

Not only did this test launch international attention on debris in space, but it reaffirmed uncertainty in operating in space for many private and public space entities. Space debris, or space “junk” as it is commonly referred to, can range from outdated satellites, to tiny fragments of broken up objects, similar to what the Russian ASAT test created.

The junk clogs up orbital pathways and can cause unforeseen structural damage to orbiting or launching objects. As such, many companies, including Astroscale have condemned ASAT tests in the industry as irresponsible behavior.

While space debris continues to orbit, Blackerby highlighted some silver-linings on the situation, “It’s awareness…when do we see the non-space media and community get in…We had recognition by politicians around the world that this was bad.”

Though not catastrophic in the near-term, the test created so much debris that the resulting awareness in the international community can be viewed as a positive aspect, but not one that the space industry wants to repeat as a normative action.

On ASAT tests, Weeden was firm that we can not allow this activity to, “live in the space environment.” Space actors can not continue doing these tests and apologizing as if they do not have any future, long-term consequences.

“I’m hopeful this will galvanize some sort of ASAT ban,” said Weeden. Given the international attention, the need to get rid of space trash is front and center and a ban on ASAT tests will help keep space accessible to all.

More in This Series

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

CB
Chris Blackerby

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers has terminated its agreement with Cellares, which raises concerns about the standardized capacity for cell therapy production. This decision highlights the importance of aligning manufacturing processes with production capabilities, rather than merely focusing on the availability of factory slots.

  • 01Bristol Myers has terminated its agreement with Cellares, affecting cell therapy capacity.
  • 02Aligning process fit with production capabilities is crucial for cell therapy success.
  • 03Factory slots alone are not sufficient to ensure supply plans in cell therapy production.

Aug 26, 2026

Argonne’s AI agents push materials R&D toward days-long cycles

Argonne’s AI agents push materials R&D toward days-long cycles

Argonne National Laboratory is utilizing AI agents to accelerate materials R&D cycles, reducing the time span to just a few days. This advancement hinges on prioritizing dataflow and security over larger AI models. The novel approach aims to streamline processes and enhance the efficiency of research and development activities.

  • 01Argonne National Laboratory is using AI agents to significantly shorten materials R&D cycles.
  • 02The focus of procurement has shifted to dataflow and security rather than larger AI models.
  • 03Improved workflows facilitate more efficient research and development efforts.

Aug 25, 2026

Cancer diagnostics growth is forcing labs to budget for data, not just instruments

Cancer diagnostics growth is forcing labs to budget for data, not just instruments

The growth in cancer diagnostics is prompting laboratories to allocate budgets not only for instruments but also for data management. Market forecasts predict an increase in the cancer diagnostics market from $29.86 billion in 2026 to $44.92 billion by 2031. Staffing is identified as a significant operational constraint according to industry insights.

  • 01Cancer diagnostics market is expected to grow from $29.86 billion in 2026 to $44.92 billion by 2031.
  • 02Laboratories are increasingly required to budget for data management alongside instruments.
  • 03Staffing is a major operational constraint in the growth of cancer diagnostics.

Aug 24, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512